Zoetis Inc. (NYSE:ZTS – Free Report) – Equities research analysts at Zacks Research reduced their FY2026 EPS estimates for Zoetis in a research note issued to investors on Thursday, March 6th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings of $6.55 per share for the year, down from their prior estimate of $6.97. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis’ Q4 2026 earnings at $1.66 EPS.
Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%.
View Our Latest Analysis on Zoetis
Zoetis Stock Performance
NYSE:ZTS opened at $170.34 on Monday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a market capitalization of $76.28 billion, a price-to-earnings ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94. The company’s 50-day moving average is $166.72 and its two-hundred day moving average is $176.74. Zoetis has a 1-year low of $144.80 and a 1-year high of $200.33.
Institutional Investors Weigh In On Zoetis
Large investors have recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its position in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC purchased a new stake in shares of Zoetis in the 4th quarter valued at approximately $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis in the 3rd quarter valued at approximately $31,000. Finally, First Personal Financial Services purchased a new stake in shares of Zoetis in the 3rd quarter valued at approximately $33,000. 92.80% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.
Zoetis Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is currently 36.56%.
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
- Five stocks we like better than Zoetis
- The 3 Best Blue-Chip Stocks to Buy Now
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- Investing in Construction Stocks
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- 3 Healthcare Dividend Stocks to Buy
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.